US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lipella Pharmaceuticals Inc

2.58

+0.17007.05%

Post-market: 2.580.00000.00%18:31 EDT

Volume:55.35K

Turnover:133.16K

Market Cap:6.58M

PE:-0.54

High:2.58

Open:2.36

Low:2.25

Close:2.41

Loading ...

Overview Company News Filings

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Inc - to Submit Ind Application for Phase 2B Trial in Late 2025

THOMSON REUTERS

Lipella Pharmaceuticals Inc - Lp-310 Shows Statistically Significant Improvements at 0.50 Mg Dose

THOMSON REUTERS

Lipella Pharmaceuticals Inc - Final Topline Data From 1.0 Mg Cohort Expected in Q2 2025

THOMSON REUTERS

Lipella Reports Positive Phase 2a Results From Second Lp-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

THOMSON REUTERS

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Inc - to Submit Ind Application for Phase 2B Trial in Late 2025

THOMSON REUTERS

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of Lp-310 for Oral Lichen Planus

THOMSON REUTERS

Lipella Pharmaceuticals Inc - Topline Results From Final Cohort Expected in Q2 2025

THOMSON REUTERS

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Spartan Capital Securities, LLC Announces Key February Transactions

Spartan Capital Securities, Llc Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

THOMSON REUTERS

Sector Update: Health Care Stocks Fall in Late Afternoon Trading

MT Newswires Live

Top Midday Gainers

MT Newswires Live

Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment

MT Newswires Live

Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

Lipella Pharmaceuticals Shares up 41.9% After Inflammatory Disease Drug Found Safe in Study

THOMSON REUTERS

BUZZ-Lipella jumps after inflammatory disease drug found safe in study

Lipella Pharmaceuticals Inc - Lp-310 Shows Clinically Meaningful Reductions in Pain, Ulceration, Inflammation

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LIPO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LIPO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIPO\",,,,,undefined,":{"symbol":"LIPO","market":"US","secType":"STK","nameCN":"Lipella Pharmaceuticals Inc","latestPrice":2.58,"timestamp":1745524800000,"preClose":2.41,"halted":0,"volume":55350,"hourTrading":{"tag":"盘后","latestPrice":2.58,"preClose":2.58,"latestTime":"18:31 EDT","volume":395,"amount":992.53,"timestamp":1745533885870},"delay":0,"floatShares":2326756,"shares":2548811,"eps":-4.789999,"marketStatus":"Not Yet Opened","change":0.17,"latestTime":"04-24 16:00:00 EDT","open":2.355,"high":2.58,"low":2.25,"amount":133157.32155,"amplitude":0.136929,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.789999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745568000000},"marketStatusCode":0,"adr":0,"listingDate":1671512400000,"exchange":"NASDAQ","adjPreClose":2.41,"preHourTrading":{"tag":"盘前","latestPrice":2.41,"preClose":2.41,"latestTime":"08:20 EDT","volume":1217,"amount":2930.3749909000003,"timestamp":1745497230567},"postHourTrading":{"tag":"盘后","latestPrice":2.58,"preClose":2.58,"latestTime":"18:31 EDT","volume":395,"amount":992.53,"timestamp":1745533885870},"volumeRatio":0.097691},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIPO\",,,,,undefined,":{"symbol":"LIPO","floatShares":2326756,"roa":"-101.59%","roe":"-198.12%","lyrEps":-4.785666,"volumeRatio":0.097691,"shares":2548811,"dividePrice":0,"high":2.58,"amplitude":0.136929,"preClose":2.41,"low":2.25,"week52Low":1.965,"pbRate":"3.43","psRate":"12.26","week52High":12,"institutionHeld":0,"latestPrice":2.58,"eps":-4.789999,"divideRate":0,"volume":55350,"delay":0,"ttmEps":-4.789999,"open":2.355,"prevYearClose":3.05,"prevWeekClose":2.4,"prevMonthClose":2.51,"prevQuarterClose":2.51,"fiveDayClose":2.41,"twentyDayClose":2.6,"sixtyDayClose":2.7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LIPO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529500447","title":"Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”","url":"https://stock-news.laohu8.com/highlight/detail?id=2529500447","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529500447?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:30","pubTimestamp":1745411400,"startTime":"0","endTime":"0","summary":"Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute. Topline study results demonstrate clinically meaningful improvements in OLP. Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity. PITTSBURGH, April 23, 2025  -- Lipella Pharmaceuticals Inc.  , a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus  has been accepted for podium presentation at the 2025 joint international meeting of the American Academy of Oral Medicine  and European Association of Oral Medicine . The meeting will take place May 14–17 in Las Vegas. The presentation will be delivered by Dr. Alessandro Villa, Chief of Oral Medicine, Oral Oncology and Dentistry, and Professor at Herbert Wertheim College of Medicine, Miami Cancer Institute, on May 15.About the StudyThe Oral Lichen Planus Phase 2a tri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-abstract-oral-lichen-123000134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4160","OLP","EAOM","LIPO","BK4139"],"gpt_icon":0},{"id":"2529324858","title":"Lipella Pharmaceuticals Inc - to Submit Ind Application for Phase 2B Trial in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529324858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529324858?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:30","pubTimestamp":1745314200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA8LMHN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2529324833","title":"Lipella Pharmaceuticals Inc - Lp-310 Shows Statistically Significant Improvements at 0.50 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2529324833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529324833?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:30","pubTimestamp":1745314200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA8LMHN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2529324832","title":"Lipella Pharmaceuticals Inc - Final Topline Data From 1.0 Mg Cohort Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529324832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529324832?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:30","pubTimestamp":1745314200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA8LMHN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2529215453","title":"Lipella Reports Positive Phase 2a Results From Second Lp-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529215453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529215453?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:30","pubTimestamp":1745314200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA8LMHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2529322583","title":"Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529322583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529322583?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:30","pubTimestamp":1745314200,"startTime":"0","endTime":"0","summary":"Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse. Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts. Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement. Treatment with LP-310 at the 0.50 mg dose demonstrated statistically significant improvements in multiple patient-reported and investigator-measured efficacy endpoints, reinforcing LP-310’s potential as a non-steroidal, locally delivered therapy for OLP. The trial, currently active across seven U.S. study sites, has now progressed to the third and highest dose cohort , with topline results expected in the second quarter of 2025.LP-310 continues to be well tolerated, with no treatment-related SAEs and no patient dropouts. All participants successfully adhered to the twice-daily 10-milliliter rinse regimen. Pharmacokinetic analysis confirmed that tacrolimus levels remained undetectable or minimal in all patients, reinforcing LP-310’s abil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-reports-positive-phase-2a-093000375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IGA","LIPO","BK4139","BK4160","OLP"],"gpt_icon":0},{"id":"2525857255","title":"Lipella Pharmaceuticals Inc - to Submit Ind Application for Phase 2B Trial in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525857255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525857255?lang=en_us&edition=fundamental","pubTime":"2025-04-08 17:00","pubTimestamp":1744102800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nTUA2HJTHQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2525857251","title":"Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of Lp-310 for Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2525857251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525857251?lang=en_us&edition=fundamental","pubTime":"2025-04-08 17:00","pubTimestamp":1744102800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nTUA2HJTHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2525254857","title":"Lipella Pharmaceuticals Inc - Topline Results From Final Cohort Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525254857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525254857?lang=en_us&edition=fundamental","pubTime":"2025-04-08 17:00","pubTimestamp":1744102800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nTUA2HJTHQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2525119850","title":"Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2525119850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525119850?lang=en_us&edition=fundamental","pubTime":"2025-04-08 17:00","pubTimestamp":1744102800,"startTime":"0","endTime":"0","summary":"PITTSBURGH, April 08, 2025  -- Lipella Pharmaceuticals Inc.  , a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus . The Phase 2a trial has now fully enrolled participants across all three dose cohorts  at seven U.S. study sites. Topline results from the final cohort  remain on track for the second quarter of 2025 and will represent the most comprehensive clinical dataset to date for LP-310.About Lipella Pharmaceuticals Inc.Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-completes-enrollment-phase-090000279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LIPO","OLP","BK4160"],"gpt_icon":0},{"id":"2517945469","title":"Spartan Capital Securities, LLC Announces Key February Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2517945469","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517945469?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:56","pubTimestamp":1741384560,"startTime":"0","endTime":"0","summary":"New York, NY, March 07, 2025  -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc.  in a $3.788 million private placement. This financing represents an important milestone in Lipella’s efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman.“These transactions highlight Spartan Capital’s ability to deliver meaningful results for our clients,” said John Lowry, CEO of Spartan Capital Securities, LLC. “We take pride in our role as a trusted partner, helping companies secure the capital they need to fuel innovation, execute strategic growth initiatives, and drive long-term success. Our investment banking team remains","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spartan-capital-securities-llc-announces-215600377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCTI","SPAQ.U","LIPO","BK4167"],"gpt_icon":0},{"id":"2517078376","title":"Spartan Capital Securities, Llc Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2517078376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517078376?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:18","pubTimestamp":1741112312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6QYMKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510540763","title":"Sector Update: Health Care Stocks Fall in Late Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2510540763","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510540763?lang=en_us&edition=fundamental","pubTime":"2025-02-12 04:56","pubTimestamp":1739307384,"startTime":"0","endTime":"0","summary":"Health care stocks were down  late Tuesday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund  shedding 0.1%.The iShares Biotechnology ETF  fell 1.4%.In corporate news, Travere Therapeutics  shares rose 13% after the company said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.Firefly Neuroscience  shares surged 174% after it said it was accepted into Nvidia's  Connect program.Novartis  agreed to buy biopharmaceutical firm Anthos Therapeutics for up to $3.1 billion as the Swiss pharmaceutical giant expands its cardiovascular portfolio. Novartis shares added 0.8%.Lipella Pharmaceuticals  shares jumped 35% after it reported positive topline results from a phase 2a trial of LP-310, a liposomal-tacrolimus oral rinse for oral lichen planus.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z8X17.USD","3NVD.UK","LU0861579265.USD","NVDS.UK","LU2360032135.SGD","LU0868494708.USD","LU2125154778.USD","LU2326559502.SGD","LU2592432038.USD","LIPO","NVDU","LU1951200564.SGD","LU1935042991.SGD","NVDA","LU2471134952.CNY","BK4548","LU0211331839.USD","LU0320765059.SGD","SG9999015978.USD","LU1066051498.USD","IE00BFSS7M15.SGD","NVD","2NVD.UK","LU1815336760.USD","LU1280957306.USD","LU1244550577.SGD","SNVD.UK","NVD2.UK","AIFF","LU2361044949.HKD","NVD3.UK","BK4581","NVDS","SGXZ51526630.SGD","LU2125909759.SGD","LU0289960550.SGD","LU0672654240.SGD","IBB","BK4167","TVTX","LU0069063385.USD","NVDD","NVDY","NVIW.SI","SG9999001424.SGD","NVDX","XLV","LU0642271901.SGD","NVS"],"gpt_icon":1},{"id":"2510353188","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353188","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510353188?lang=en_us&edition=fundamental","pubTime":"2025-02-12 02:34","pubTimestamp":1739298847,"startTime":"0","endTime":"0","summary":"Firefly Neuroscience  shares were up more than 170% in recent trading after the company said it was accepted into the Nvidia  Connect program.Intraday trading volume catapulted to over 155 million shares from a daily average of about 2.48 million.Lipella Pharmaceuticals  said its treatment candidate for oral lichen planus showed \"clinically meaningful\" reductions in pain, ulceration, and inflammation across all key metrics in a phase 2a trial.Shares soared about 36% as intraday trading volume surged to over 37.2 million from a daily average of about 1.59 million.Travere Therapeutics  said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari for focal segmental glomerulosclerosis, a rare kidney disorder.Wedbush raised its price target on the stock to $30 from $26 while maintaining its outperform rating.Shares of Travere rose 13% as intraday trading volume climbed to over 3.62 million from a daily","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1935042991.SGD","LU2357125470.USD","NVDD","LU1037948541.HKD","LU2430703178.SGD","IE00BYXW3230.USD","LU0528227936.USD","LU0965509283.SGD","LU1642822529.SGD","LU2461242641.AUD","LU0107464264.USD","LU2265009873.SGD","NVDS.UK","LU0345768153.USD","BK4598","LU1674673428.USD","SG9999002232.USD","BK4608","LU1280957306.USD","NVDY","IE00B3M56506.USD","LU0096362180.USD","SNVD.UK","LU0048584097.USD","IE00BK4W5M84.HKD","LIPO","HK0000306701.USD","NVDX","BK4554","NVD","LU0069063385.USD","LU2505996681.GBP","3NVD.UK","TVTX","LU0072462426.USD","LU2242650005.HKD","NVDU","LU0417517546.SGD","2NVD.UK","NVD3.UK","NVIW.SI","AIFF","NVDS","LU1720051017.SGD","NVDA","NVD2.UK","LU1429558221.USD","LU2430703095.HKD","LU2750360641.GBP"],"gpt_icon":1},{"id":"2510589363","title":"Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2510589363","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510589363?lang=en_us&edition=fundamental","pubTime":"2025-02-12 02:10","pubTimestamp":1739297401,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals' (LIPO) shares jumped nearly 35% in recent Tuesday trading after the company reported positive topline results from its phase 2a multicenter dose-ranging trial of LP-310, a lip","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2510133026","title":"Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2510133026","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510133026?lang=en_us&edition=fundamental","pubTime":"2025-02-12 01:56","pubTimestamp":1739296560,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus.The biotechnology company said LP-310 demonstrated a strong safety profile, with no product-related serious adverse events and no patient dropouts.Oral lichen planus is a chronic inflammatory condition that affects the mucous membranes inside the mouth, on the tongue, cheeks, gums or palate.The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks one, four and six, Lipella said.The trial, which is active across seven U.S. sites, has progressed to the next higher dose cohort of 0.5 mg/10 mL.Lipella continues to recruit for the trial, with plans to activate additional sites and complete the trial by mid-2025. The company is preparing for key miles","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2510339585","title":"Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes","url":"https://stock-news.laohu8.com/highlight/detail?id=2510339585","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510339585?lang=en_us&edition=fundamental","pubTime":"2025-02-11 23:52","pubTimestamp":1739289156,"startTime":"0","endTime":"0","summary":"On Tuesday, Lipella Pharmaceuticals Inc.  shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus .LP-310 demonstrated a strong safety profile, with no product-related serious adverse events  or patient dropouts.The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1, 4, and 6.LP-310 is the only oral rinse topical treatment currently in development for OLP.Affecting about 6 million Americans, OLP is a chronic inflammatory condition that targets mucous membranes in the mouth, which can cause pain and make eating, drinking, and even speaking uncomfortable.Characterized by symptoms such as burning pain, white patches, swollen tissue and open sores, OLP has no FDA-approved therapies.The trial showed significant improvements across multiple efficacy endpoints while suggesting the safety an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nano-cap-lipella-pharmaceuticals-stock-155236668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4160","OLP","LIPO","BK4139"],"gpt_icon":0},{"id":"2510382002","title":"Lipella Pharmaceuticals Shares up 41.9% After Inflammatory Disease Drug Found Safe in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382002?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:32","pubTimestamp":1739284332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P211L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510334807","title":"BUZZ-Lipella jumps after inflammatory disease drug found safe in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2510334807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510334807?lang=en_us&edition=fundamental","pubTime":"2025-02-11 19:50","pubTimestamp":1739274624,"startTime":"0","endTime":"0","summary":"BUZZ-Lipella jumps after inflammatory disease drug found safe in study ** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket ** LIPO says its exper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4N3P20OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2510880971","title":"Lipella Pharmaceuticals Inc - Lp-310 Shows Clinically Meaningful Reductions in Pain, Ulceration, Inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2510880971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510880971?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LIPO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-08","symbol":"LIPO","defaultRemindTime":1731076200000,"type":"split","dateTimestamp":1731042000000,"forFactor":8,"toFactor":1,"ratio":8},{"market":"US","date":"2023-05-15","symbol":"LIPO","fiscalQuarterEnding":"2023/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1684123200000,"reportTimeType":"","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LIPO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LIPO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1712721600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LIPO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LIPO","date":"2025-04-23","current":-1.216922,"percent":0.55814,"low":-12.613414,"twenty":-4.051571,"median":-1.351639,"eighty":-0.86179,"high":-0.60491,"avg":-2.298002,"sd":1.876995,"marketCap":6104402},"quantilePoints":[{"date":"2022-12-16","current":-9.212167,"twenty":-9.212167,"median":-9.212167,"eighty":-9.212167,"marketCap":24121664},{"date":"2022-12-23","current":-8.796705,"twenty":-10.332031,"median":-9.541768,"eighty":-8.796705,"marketCap":23033793},{"date":"2022-12-30","current":-6.866084,"twenty":-9.963501,"median":-8.774659,"eighty":-7.296038,"marketCap":17978547},{"date":"2023-01-06","current":-6.778339,"twenty":-9.475847,"median":-7.710635,"eighty":-6.892408,"marketCap":17748790},{"date":"2023-01-13","current":-6.986735,"twenty":-8.96289,"median":-7.041576,"eighty":-6.892408,"marketCap":18294464},{"date":"2023-01-20","current":-5.506029,"twenty":-8.779068,"median":-7.019639,"eighty":-6.795888,"marketCap":14417301},{"date":"2023-01-27","current":-5.286666,"twenty":-8.471827,"median":-6.909957,"eighty":-5.628873,"marketCap":13842907},{"date":"2023-02-03","current":-5.945196,"twenty":-8.041874,"median":-6.822212,"eighty":-5.484093,"marketCap":15567239},{"date":"2023-02-10","current":-5.725393,"twenty":-7.77425,"median":-6.690594,"eighty":-5.492867,"marketCap":14991696},{"date":"2023-02-17","current":-5.176984,"twenty":-7.252165,"median":-6.47123,"eighty":-5.453382,"marketCap":13555710},{"date":"2023-02-24","current":-4.628794,"twenty":-7.037189,"median":-6.207993,"eighty":-5.374411,"marketCap":12120298},{"date":"2023-03-03","current":-3.970483,"twenty":-7.019639,"median":-5.879167,"eighty":-5.299828,"marketCap":10396540},{"date":"2023-03-10","current":-4.277592,"twenty":-7.013058,"median":-5.725393,"eighty":-4.705879,"marketCap":11200692},{"date":"2023-03-17","current":-5.176984,"twenty":-6.971379,"median":-5.495061,"eighty":-4.654898,"marketCap":13555710},{"date":"2023-03-24","current":-4.606638,"twenty":-6.909957,"median":-5.484093,"eighty":-4.654898,"marketCap":12062284},{"date":"2023-03-31","current":-4.277592,"twenty":-6.901182,"median":-5.467641,"eighty":-4.545216,"marketCap":11200692},{"date":"2023-04-06","current":-4.321465,"twenty":-6.866084,"median":-5.434736,"eighty":-4.321465,"marketCap":11315571},{"date":"2023-04-14","current":-3.935887,"twenty":-6.822212,"median":-5.374411,"eighty":-4.277592,"marketCap":10224222},{"date":"2023-04-21","current":-4.223339,"twenty":-6.822212,"median":-5.352475,"eighty":-4.223339,"marketCap":10970934},{"date":"2023-04-28","current":-4.798244,"twenty":-6.778339,"median":-5.176984,"eighty":-4.223339,"marketCap":12464360},{"date":"2023-05-04","current":-4.245451,"twenty":-6.637946,"median":-5.176984,"eighty":-4.218917,"marketCap":11028374},{"date":"2023-05-12","current":-4.11278,"twenty":-6.585299,"median":-4.826002,"eighty":-4.16573,"marketCap":10683737},{"date":"2023-05-19","current":-3.649357,"twenty":-6.493166,"median":-4.751857,"eighty":-4.122361,"marketCap":10683737},{"date":"2023-05-26","current":-3.433535,"twenty":-6.365146,"median":-4.672447,"eighty":-4.090947,"marketCap":10051903},{"date":"2023-06-02","current":-3.747458,"twenty":-6.259851,"median":-4.628794,"eighty":-4.046445,"marketCap":10970934},{"date":"2023-06-09","current":-3.727838,"twenty":-6.129022,"median":-4.551797,"eighty":-4.001194,"marketCap":10913495},{"date":"2023-06-16","current":-4.218343,"twenty":-5.984418,"median":-4.47502,"eighty":-3.990004,"marketCap":12349481},{"date":"2023-06-23","current":-3.957002,"twenty":-5.918785,"median":-4.356009,"eighty":-3.989199,"marketCap":11584388},{"date":"2023-06-30","current":-3.825939,"twenty":-5.813139,"median":-4.321465,"eighty":-3.98011,"marketCap":11200692},{"date":"2023-07-07","current":-4.218343,"twenty":-5.760491,"median":-4.296824,"eighty":-3.986737,"marketCap":12349481},{"date":"2023-07-14","current":-4.198723,"twenty":-5.747329,"median":-4.283633,"eighty":-3.991615,"marketCap":12292042},{"date":"2023-07-21","current":-4.002521,"twenty":-5.72978,"median":-4.277592,"eighty":-3.991615,"marketCap":11717647},{"date":"2023-07-28","current":-4.041761,"twenty":-5.637647,"median":-4.25662,"eighty":-3.991615,"marketCap":11832526},{"date":"2023-08-04","current":-3.806319,"twenty":-5.598162,"median":-4.245451,"eighty":-3.987295,"marketCap":11143253},{"date":"2023-08-11","current":-3.952489,"twenty":-5.523578,"median":-4.220841,"eighty":-3.9829,"marketCap":11571177},{"date":"2023-08-18","current":-3.197951,"twenty":-5.48848,"median":-4.218343,"eighty":-3.967787,"marketCap":11781979},{"date":"2023-08-25","current":-3.086945,"twenty":-5.484093,"median":-4.199975,"eighty":-3.935362,"marketCap":11373011},{"date":"2023-09-01","current":-3.118127,"twenty":-5.475319,"median":-4.198723,"eighty":-3.901869,"marketCap":11487890},{"date":"2023-09-08","current":-3.349959,"twenty":-5.466544,"median":-4.179116,"eighty":-3.818091,"marketCap":12342014},{"date":"2023-09-15","current":-3.289623,"twenty":-5.448995,"median":-4.170269,"eighty":-3.775494,"marketCap":12119723},{"date":"2023-09-21","current":-3.086945,"twenty":-5.435833,"median":-4.15149,"eighty":-3.747458,"marketCap":11373011},{"date":"2023-09-29","current":-2.400958,"twenty":-5.415655,"median":-4.124038,"eighty":-3.684673,"marketCap":8845675},{"date":"2023-10-06","current":-1.808513,"twenty":-5.38692,"median":-4.117949,"eighty":-3.617494,"marketCap":6662976},{"date":"2023-10-13","current":-1.460979,"twenty":-5.374411,"median":-4.106701,"eighty":-3.366674,"marketCap":5382578},{"date":"2023-10-20","current":-2.536312,"twenty":-5.370024,"median":-4.090812,"eighty":-3.295859,"marketCap":9344351},{"date":"2023-10-27","current":-1.811651,"twenty":-5.361249,"median":-4.090812,"eighty":-3.289623,"marketCap":6674536},{"date":"2023-11-03","current":-1.811651,"twenty":-5.352475,"median":-4.080243,"eighty":-3.225702,"marketCap":6674536},{"date":"2023-11-10","current":-1.937522,"twenty":-5.352475,"median":-4.061381,"eighty":-3.180489,"marketCap":7138271},{"date":"2023-11-17","current":-1.463141,"twenty":-5.31299,"median":-4.051571,"eighty":-3.149319,"marketCap":6282770},{"date":"2023-11-24","current":-1.446253,"twenty":-5.242793,"median":-4.046445,"eighty":-3.139965,"marketCap":6210221},{"date":"2023-12-01","current":-1.527352,"twenty":-5.176984,"median":-4.041761,"eighty":-3.108772,"marketCap":6558457},{"date":"2023-12-08","current":-1.392188,"twenty":-5.080464,"median":-4.029217,"eighty":-2.701857,"marketCap":5978063},{"date":"2023-12-15","current":-1.316496,"twenty":-4.900586,"median":-4.022141,"eighty":-2.447729,"marketCap":5653042},{"date":"2023-12-22","current":-1.208365,"twenty":-4.830389,"median":-4.008439,"eighty":-2.28715,"marketCap":5188726},{"date":"2023-12-29","current":-1.365155,"twenty":-4.804066,"median":-4.002521,"eighty":-1.937522,"marketCap":5861984},{"date":"2024-01-05","current":-1.473286,"twenty":-4.800573,"median":-3.990407,"eighty":-1.821103,"marketCap":6326300},{"date":"2024-01-12","current":-1.392188,"twenty":-4.770412,"median":-3.9829,"eighty":-1.808981,"marketCap":5978063},{"date":"2024-01-19","current":-1.31136,"twenty":-4.728868,"median":-3.970483,"eighty":-1.794113,"marketCap":5630987},{"date":"2024-01-26","current":-1.378671,"twenty":-4.685609,"median":-3.952979,"eighty":-1.753879,"marketCap":5920023},{"date":"2024-02-02","current":-1.438059,"twenty":-4.663673,"median":-3.933261,"eighty":-1.565197,"marketCap":6175035},{"date":"2024-02-09","current":-1.409862,"twenty":-4.641824,"median":-3.90442,"eighty":-1.542058,"marketCap":6053956},{"date":"2024-02-16","current":-1.409721,"twenty":-4.619932,"median":-3.845559,"eighty":-1.523065,"marketCap":6053350},{"date":"2024-02-23","current":-1.409862,"twenty":-4.597863,"median":-3.806319,"eighty":-1.484348,"marketCap":6053956},{"date":"2024-03-01","current":-1.407249,"twenty":-4.558378,"median":-3.783901,"eighty":-1.464948,"marketCap":6500035},{"date":"2024-03-08","current":-1.001041,"twenty":-4.52863,"median":-3.767078,"eighty":-1.446253,"marketCap":4623773},{"date":"2024-03-15","current":-1.125258,"twenty":-4.478872,"median":-3.737648,"eighty":-1.433801,"marketCap":5197526},{"date":"2024-03-22","current":-1.181039,"twenty":-4.47333,"median":-3.708218,"eighty":-1.423961,"marketCap":5455176},{"date":"2024-03-28","current":-1.097365,"twenty":-4.466568,"median":-3.649357,"eighty":-1.409862,"marketCap":5068689},{"date":"2024-04-05","current":-1.032742,"twenty":-4.356009,"median":-3.619338,"eighty":-1.409862,"marketCap":4770199},{"date":"2024-04-12","current":-1.12381,"twenty":-4.343402,"median":-3.433535,"eighty":-1.407249,"marketCap":5190837},{"date":"2024-04-19","current":-1.087153,"twenty":-4.321465,"median":-3.330705,"eighty":-1.393718,"marketCap":5021522},{"date":"2024-04-26","current":-1.079837,"twenty":-4.299529,"median":-3.292479,"eighty":-1.392188,"marketCap":4987730},{"date":"2024-05-03","current":-1.143088,"twenty":-4.296824,"median":-3.274033,"eighty":-1.378671,"marketCap":5279884},{"date":"2024-05-10","current":-1.234958,"twenty":-4.296824,"median":-3.235056,"eighty":-1.367566,"marketCap":5704227},{"date":"2024-05-17","current":-1.222599,"twenty":-4.289674,"median":-3.197016,"eighty":-1.351639,"marketCap":5798727},{"date":"2024-05-24","current":-1.049613,"twenty":-4.277592,"median":-3.180489,"eighty":-1.349994,"marketCap":4978261},{"date":"2024-05-31","current":-1.00271,"twenty":-4.277592,"median":-3.180489,"eighty":-1.311306,"marketCap":4755804},{"date":"2024-06-07","current":-1.039111,"twenty":-4.277592,"median":-3.149308,"eighty":-1.297195,"marketCap":4928452},{"date":"2024-06-14","current":-1.07439,"twenty":-4.271575,"median":-3.141522,"eighty":-1.250266,"marketCap":5095776},{"date":"2024-06-21","current":-1.032697,"twenty":-4.263571,"median":-3.133639,"eighty":-1.226278,"marketCap":4898029},{"date":"2024-06-28","current":-0.721124,"twenty":-4.259579,"median":-3.125844,"eighty":-1.221938,"marketCap":3420254},{"date":"2024-07-05","current":-0.708777,"twenty":-4.256427,"median":-3.094741,"eighty":-1.209762,"marketCap":3361691},{"date":"2024-07-12","current":-0.851494,"twenty":-4.249533,"median":-2.884267,"eighty":-1.191679,"marketCap":4038592},{"date":"2024-07-15","current":-0.737801,"twenty":-4.247492,"median":-2.732258,"eighty":-1.187013,"marketCap":3499353},{"date":"2024-08-02","current":-1.241241,"twenty":-4.245451,"median":-2.58025,"eighty":-1.188507,"marketCap":5887142},{"date":"2024-08-09","current":-1.095615,"twenty":-4.245451,"median":-2.515407,"eighty":-1.188507,"marketCap":5196448},{"date":"2024-08-16","current":-1.019849,"twenty":-4.226214,"median":-2.400958,"eighty":-1.17357,"marketCap":4224631},{"date":"2024-08-23","current":-0.821535,"twenty":-4.223339,"median":-2.29575,"eighty":-1.143088,"marketCap":3403136},{"date":"2024-08-30","current":-0.830535,"twenty":-4.218343,"median":-1.937522,"eighty":-1.134096,"marketCap":3440417},{"date":"2024-09-06","current":-0.792384,"twenty":-4.218343,"median":-1.827405,"eighty":-1.121965,"marketCap":3282377},{"date":"2024-09-13","current":-0.738971,"twenty":-4.218343,"median":-1.811651,"eighty":-1.109163,"marketCap":3061121},{"date":"2024-09-20","current":-0.831514,"twenty":-4.218343,"median":-1.808513,"eighty":-1.097365,"marketCap":3444470},{"date":"2024-09-27","current":-0.993512,"twenty":-4.20465,"median":-1.794411,"eighty":-1.092727,"marketCap":4115534},{"date":"2024-10-04","current":-0.771253,"twenty":-4.199224,"median":-1.780144,"eighty":-1.087001,"marketCap":3194847},{"date":"2024-10-11","current":-0.786319,"twenty":-4.198723,"median":-1.74076,"eighty":-1.078748,"marketCap":3257253},{"date":"2024-10-18","current":-1.056023,"twenty":-4.198723,"median":-1.581417,"eighty":-1.066515,"marketCap":4374480},{"date":"2024-10-25","current":-0.995085,"twenty":-4.198723,"median":-1.552404,"eighty":-1.063983,"marketCap":4122051},{"date":"2024-10-31","current":-0.953293,"twenty":-4.186959,"median":-1.545599,"eighty":-1.057071,"marketCap":3948928},{"date":"2024-11-08","current":-0.730787,"twenty":-4.179108,"median":-1.540868,"eighty":-1.050144,"marketCap":3027220},{"date":"2024-11-15","current":-0.735457,"twenty":-4.175218,"median":-1.523778,"eighty":-1.043965,"marketCap":3046564},{"date":"2024-11-22","current":-0.686217,"twenty":-4.169798,"median":-1.500319,"eighty":-1.040265,"marketCap":2925668},{"date":"2024-11-29","current":-0.881848,"twenty":-4.163548,"median":-1.473306,"eighty":-1.032715,"marketCap":3759738},{"date":"2024-12-06","current":-0.876177,"twenty":-4.152592,"median":-1.464996,"eighty":-1.024615,"marketCap":3735559},{"date":"2024-12-13","current":-0.731565,"twenty":-4.139606,"median":-1.460979,"eighty":-1.004487,"marketCap":3119011},{"date":"2024-12-20","current":-0.72873,"twenty":-4.127646,"median":-1.446253,"eighty":-0.99776,"marketCap":3106921},{"date":"2024-12-27","current":-0.941394,"twenty":-4.124038,"median":-1.442156,"eighty":-0.992392,"marketCap":4013611},{"date":"2025-01-03","current":-0.901697,"twenty":-4.124038,"median":-1.432737,"eighty":-0.97594,"marketCap":3844362},{"date":"2025-01-10","current":-0.898861,"twenty":-4.121001,"median":-1.423961,"eighty":-0.960116,"marketCap":3832273},{"date":"2025-01-17","current":-0.827973,"twenty":-4.116572,"median":-1.42078,"eighty":-0.950913,"marketCap":3530043},{"date":"2025-01-24","current":-0.83648,"twenty":-4.11393,"median":-1.409862,"eighty":-0.928165,"marketCap":3566311},{"date":"2025-01-31","current":-0.757085,"twenty":-4.105485,"median":-1.409862,"eighty":-0.901697,"marketCap":3227813},{"date":"2025-02-07","current":-1.318519,"twenty":-4.094929,"median":-1.409862,"eighty":-0.897954,"marketCap":5621473},{"date":"2025-02-14","current":-1.139881,"twenty":-4.09094,"median":-1.408485,"eighty":-0.896593,"marketCap":4859854},{"date":"2025-02-21","current":-0.969749,"twenty":-4.090812,"median":-1.403855,"eighty":-0.8975,"marketCap":4134502},{"date":"2025-02-28","current":-0.833644,"twenty":-4.090812,"median":-1.395763,"eighty":-0.89411,"marketCap":3554221},{"date":"2025-03-07","current":-0.723059,"twenty":-4.090755,"median":-1.392188,"eighty":-0.885409,"marketCap":3082743},{"date":"2025-03-14","current":-0.62098,"twenty":-4.082329,"median":-1.392188,"eighty":-0.878445,"marketCap":2647532},{"date":"2025-03-21","current":-0.737236,"twenty":-4.069314,"median":-1.37955,"eighty":-0.864835,"marketCap":3143189},{"date":"2025-03-28","current":-0.771262,"twenty":-4.065687,"median":-1.378671,"eighty":-0.861371,"marketCap":3288259},{"date":"2025-04-04","current":-1.270273,"twenty":-4.061381,"median":-1.373118,"eighty":-0.857462,"marketCap":6372027},{"date":"2025-04-11","current":-1.219463,"twenty":-4.057457,"median":-1.365155,"eighty":-0.859879,"marketCap":6117146},{"date":"2025-04-17","current":-1.224544,"twenty":-4.051571,"median":-1.351639,"eighty":-0.861161,"marketCap":6142634},{"date":"2025-04-23","current":-1.216922,"twenty":-4.051571,"median":-1.351639,"eighty":-0.86179,"marketCap":6104402}],"updateTime":1745566458783}}}